Latest news with #Metformin
The Hindu
8 hours ago
- Business
- The Hindu
Granules unit in Hyderabad, one of the largest globally for paracetamol API, under U.S. FDA scanner
Generic drugmaker Granules India's active pharmaceutical ingredients (API) manufacturing facility in Bonthapally, Hyderabad, has been issued an observation by the U.S. Food and Drug Administration (U.S. FDA). The Bonthapally facility is one of the world's largest single-site paracetamol API manufacturing plants by volume. Along with paracetamol APIs, the company has established Metformin and Guaifenesin API manufacturing plants in the same facility, Granules India said in an intimation to the stock exchanges on Friday. The U.S. FDA had inspected the facility, located in Sangareddy district, from June 16-20 and issued Form 483 with one observation. The company said it will respond to the observation within the stipulated time.
Business Upturn
12 hours ago
- Business
- Business Upturn
Granules India's Bonthapally facility completes US FDA inspection with one observation
By Aditya Bhagchandani Published on June 20, 2025, 16:28 IST Granules India announced on June 20, 2025, that its API Unit-I facility at Bonthapally, located in Sangareddy District near Hyderabad, has successfully completed a US FDA inspection conducted between June 16 and June 20. The inspection concluded with a single Form 483 observation. In an exchange filing, the company stated it would address the observation within the prescribed timeline. Granules emphasized that the Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing units by volume and also houses manufacturing plants for Metformin and Guaifenesin APIs. The company assured investors that the outcome will be managed in line with regulatory expectations. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Indian Express
14 hours ago
- Health
- Indian Express
Scientists say they may have found a way to extend human lifespan
For decades, scientists have been trying to find a way to extend human lifespan, and while studies have shown that select lab animals can live longer by eating less, they haven't conducted these studies on humans. A century-old study on lab rats has shown that mice who eat less often outlive their fed counterparts, but it can be almost impossible for most humans to follow a permanent diet. However, a new study by the School of Biological Sciences, University of East Anglia, claims that a combination of FDA-approved drugs that mimic the effects of dieting might be the answer to a longer life. The two drugs – Rapamycin and Metformin are known to extend the lifespan of mice as much as up to 30 per cent. Rapamycin, which was first found in the 1970s in bacteria living on the Easter Island soil, has been traditionally used as a powerful immunosuppressant to prevent organ-transplant rejection. The drug works by disabling a particular switch which is used to inform cells when a cell has an abundance of nutrients. As for Metformin, it is a synthetic compound that is found in French Lilac or Goat's Rue, which doctors prescribe to control sugar levels in type 2 diabetes. Since both of these drugs are used to sense the nutrient and energy levels in the human body, biologists wanted to see if the combination of these drugs could have the same effect as eating less. To know more about their effects, scientists say they examined thousands of existing studies and came across 167 studies that focused on eight vertebrate species, like fish and monkeys, which offered them a detailed insight into how these drugs affected animals. Out of three strategies that help with longevity, eating less, taking Rapamycin and consuming Metformin, scientists say the most dependable way to increase the lifespan is to eat less, irrespective of the animal's sex. They also noted that the second most effective strategy to increase lifespan was to take Rapamycin, while Metformin had no substantial effect. However, scientists did say that the effect of Rapamycin on animals wasn't consistent, as, in some cases, studies have shown that eating less or taking Rapamycin reduced an animal's lifespan. Another thing to note here is that most of these positive effects were on mice and rats, which have genes similar to humans but are not exactly the same. And since Rapamycin does come with some side effects, like reduced immunity, scientists are now trying to see if lower doses of the drug offer some advantages without the side effects. According to an ongoing Rapamycin trial on humans, it was noted that lower doses of the drug might help increase the lifespan. But, as of now, the trial is still in progress and will take a few years before the results are out.
The National
2 days ago
- Health
- The National
Time for a rethink about what the NHS is able to provide
I agree that we need to have a rethink about what the NHS and healthcare as a whole should do. We need to change the emphasis from treatment to cure, from prescriptions to prevention. READ MORE: NHS Grampian to scrap free nappies for newborns in bid to save £23m Using myself as an example, I have been a type-2 diabetic for almost 20 years. First I was prescribed Metformin, the dose of which was gradually ramped up, then another drug was added, then another, then another so that I almost rattle when I walk. 20 years ago, no-one said: 'Go on this diet and come back in six months, fatty'. Nobody said: 'I wonder why his pancreas suddenly stopped working properly'. Nobody ever looks at how my body is working in any detail; everyone looks at their own speciality. If they had looked at me properly 10 years ago when treating me for something trivial, they would have seen the early pathognomonic signs of the life-threatening condition I now am being treated for. I wouldn't have been on unnecessary anti-coagulants for years if an ECG recording had been examined by a cardiologist rather than someone trialling new equipment. I have had the ridiculous situation where my GP takes blood from me to check on one thing and the hospital consultant repeats the process two days later to look at another factor. READ MORE: Stephen Flynn clashes with Labour MP in BBC interview: 'Don't talk over me' Medicine and surgery have changed dramatically since the NHS was created. We need to start from scratch and decide what we can afford to do. Life is unfair, and unless the structure of society is radically changed, the majority of us can never have the same options or opportunities that are available to the top 1%. We need more staff and more funding. First of all, we need to train enough staff here in the UK rather than relying on 25% of the staff coming from overseas. Those who gain their initial degrees in Scotland and are trained by the NHS should work full-time in the NHS and the private sector should train its own staff. We need more time spent on initial consultations; regular health MOTs where every common condition that could affect a patient of that age is assessed. We need to stop providing treatments that modern medicine can do but are the 'icing on the cake'. Would society collapse if assisted reproduction wasn't available on the NHS? Should we offer bariatric surgery? I hate to say, it but should we treat OAPs like me if we can't be discharged home to look after ourselves, if the treatment simply delays the inevitable and gives no quality of life? The hospital service in Scotland will definitely collapse if 10% or more of the available beds continue to be taken up by those who do not require further inpatient treatment but just have nowhere to go. If Obergruppenfuhrer Starmer can suddenly decide to double the UK defence budget to keep Nato happy, why can't he do the same for the NHS and keep us all happy? David J Crawford Glasgow MAYBE Norman Robertson (Letters, June 17) missed the sardonic nature of my letter of June 16, but at no point did I single out Israel alone. I noted that each country was equally unstable. I also made clear Netanyahu faced internal opposition to his war from within Israel. What I find interesting is that while Israel is reported on as being a 'state' by UK media, Iran is always referred to as a 'regime'; in fact the orange king of the USA of talks of Iran in terms of a 'regime change' being needed. READ MORE: Angela Rayner does not rule out following US into war with Iran The reality is that without USA defence funding and the backing of Zionist billionaires, Israel is busted. Without a war, Netanyahu is heading for criminal fines and possible imprisonment in Israel, all before the ICC gets hold of him for war crimes in Gaza. The only one who gains from further escalation in the Middle East is Netanyahu. At no time in recent history has bombing of cities changed anyone's minds. The myth of precision bombing still leaves a lot of collateral damage. Ballistic missiles can be off their aiming point from between 200 to 500 metres, no matter their manufacturer's claims. We are now at Sarajevo in 1914 and, courtesy of Mr Starmer getting a 'trade deal' with the orange king, the UK is already being sucked into the active defence of Israel whether any voter in the UK wishes it or not, with the RAF spy plane and increased Typhoon deployment to Cyprus. The Royal Navy is already active in the Red Sea and Hormuz Strait, shooting down missiles fired from Yemen while monitoring Iranian missile launches for the US and Israeli military. READ MORE: Keir Starmer to chair emergency Cobra meeting on Middle East How far away is the UK from putting boots on the ground on behalf of the regime in Israel? I have seen 'active service', suffered having friends killed and maimed, and like many I would say that no matter how the politicians polish this particular turd, it always ends up in some form of negotiation or defeat, which raises the question 'why did we fight in the first place?' Neither Iran nor Israel are worth the death of a single UK serviceman or woman, Mr Robertson, it is as simple as that, no matter who hit who first. We are not talking about a 'jackets aff' fight at the bike sheds here, we are looking at a tipping point for World War Three. Peter Thomson Kirkcudbright
Hans India
2 days ago
- Health
- Hans India
Abbott and MSD Announce Strategic Partnership to Distribute Innovative Oral Anti-Diabetic Medicines in India
Abbott and MSD Pharmaceuticals (tradename of Merck & Co., Inc., Rahway, N.J., USA) are announcing a strategic collaboration through a distribution agreement for MSD's oral anti-diabetic medicine, Sitagliptin, its combination, Sitagliptin/Metformin, and the extended-release version in India. Under this agreement, Abbott will distribute this portfolio, leveraging its broad in-country footprint to continue to make these medicines available to people in India. MSD's Sitagliptin, its combination, and extended-release versions are marketed under the brand names Januvia, Janumet and Janumet XR. Sitagliptin is a DPP4i or Dipeptidyl Peptidase IV Inhibitor, used for the treatment of Type 2 diabetes. It was discovered and developed by MSD Pharmaceuticals and was the first DPP4i to be launched in India in 2008. The brands under this portfolio continue to be among the leaders in the category, even after loss of exclusivity. In India, at least 60 per cent of deaths are attributed to non-communicable diseases or NCDs. Amongst these, the leading causes are diabetes, cardiovascular conditions and cancer. The country has an estimated 101 million people with diabetes, and 136 million people who are pre-diabetic, and are at a higher risk of developing diabetes in the future. 'As the largest diversified healthcare company in India, Abbott is uniquely positioned to address some of the most pressing health challenges, particularly non-communicable diseases, which contribute to a considerable burden on the healthcare system,' said Ambati Venu, Vice President for Abbott in India. He further added, 'We offer a wide range of solutions to help people manage diabetes more effectively, including testing, continuous glucose monitoring, nutrition and a complete diabetes medicines portfolio. Through our extensive presence, we can help people in India better manage their Type 2 diabetes and take control of their health.' Rehan A. Khan, Managing Director, MSD India Region stated, 'Since its introduction in India over 17 years ago, our sitagliptin portfolio has positively impacted the lives of hundreds of thousands of patients across the country and has earned the trust of both doctors and patients. Our partnership with Abbott establishes a sustainable business model that will enable us to continue to serve patients throughout India with these diabetes treatments.'
